Anagliptin (INN; trade name Suiny) is a pharmaceutical drug for the treatment of type 2 diabetes mellitus. It is approved for use in Japan.[1] It belongs to the class of anti-diabetic drugs known as dipeptidyl peptidase-4 inhibitors or "gliptins".[2]
Research
A systematic review and meta-analysis of anagliptin, published in 2024, found that it is effective in lowering blood glucose in people with type 2 diabetes and that it may lower cholesterol.[3]
References
- ^ Graul AI, Lupone B, Cruces E, Stringer M (January 2013). "2012 in review - part I: the year's new drugs & biologics" (PDF). Drugs of Today. 49 (1): 33–68. doi:10.1358/dot.2013.49.1.1933991. PMID 23362494. Archived from the original (PDF) on 2013-11-03.
- ^ Kato N, Oka M, Murase T, Yoshida M, Sakairi M, Yamashita S, et al. (December 2011). "Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor". Bioorganic & Medicinal Chemistry. 19 (23): 7221–7. doi:10.1016/j.bmc.2011.09.043. PMID 22019046.
- ^ Kamrul-Hasan AB, Dutta D, Nagendra L, Sharma M, Patra S, Bhattacharya S (July 2024). "Role of anagliptin, a dipeptidyl peptidase-4 inhibitor, in managing type 2 diabetes: A systematic review and meta-analysis". Medicine. 103 (28): e38870. doi:10.1097/MD.0000000000038870. PMC 11245198. PMID 38996148.
You must be logged in to post a comment.